ZOE, the London-based personalised nutrition startup, has landed a $15 million investment from New York-based Coefficient Capital, which invested in Milano Vice last year. Other investors in the startup include Accomplice, Balderton Capital, Daphni, Ahren, THVC and Steven Bartlett’s Flight Fund. This round follows the $2.5 million funding raised back in 2023.
The funds will be used to support ZOE’s expansion plans in the US, alongside continuing to deliver long-term engagement from its community of over 100,000 members worldwide.
Diabetes, heart disease and other chronic health problems are not improving. Current approaches to address them view weight gain as the problem, rather than a symptom of poor metabolic health. ZOE uses the most advanced tests and science available to help one understand how their body works so they can reduce dietary inflammation and improve their gut health naturally.
What is Zoe?
Founded by Tim Spector, Jonathan Wolf and George Hadjigeorgiou in 2017, ZOE’s personalised nutrition programme includes comprehensive at-home tests that analyses blood sugar, blood fat responses, and the gut microbiome. It combines these results with AI and data from thousands of participants in their proprietary ZOE PREDICT studies.
The companion app combines AI with data from thousands of participants in its studies to generate personalised scores for any food or meal users eat. These scores are delivered in real-time through the app, which has hundreds of thousands of foods and thousands of meal suggestions for one to choose from. Within a few months, energy, mood, hunger, and sleep can improve, so that ZOE members feel better and live healthier.
“I am really excited that Coefficient Capital has decided to join us in our mission to improve the health of millions,” said Jonathan Wolf, cofounder and CEO of ZOE. “I’m confident their expertise in helping consumer brands to grow across the US will accelerate our own growth. The US, like the UK, is in the midst of a terrible health crisis. The food that our governments tell us is good for us is in fact causing us to feel terrible, and live fewer healthy years than our parents.”
“The way ZOE combines their own science and data to drive huge shifts in consumer behavior towards health immediately impressed us,” said Andrew Goletka, Managing Partner at Coefficient Capital. “Their work, in running the world’s biggest nutrition science study and clinical trials, sets ZOE apart in a world that’s full of health and wellness companies making false claims without regulation.”
What do we think?
The company transforms personalised nutrition by leveraging advanced tests and AI to provide actionable insights into metabolic health. With its comprehensive at-home tests and data-driven app, ZOE empowers users to improve dietary inflammation and gut health, addressing the root causes of chronic conditions.
As it expands its reach, ZOE’s innovative approach and scientific rigor position it to enhance health outcom
